Research programme: ocular therapeutics - ForSight Vision5Alternative Names: Helios™ insert
Latest Information Update: 16 Feb 2015
At a glance
- Originator ForSight VISION5
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Glaucoma; Ocular hypertension
Most Recent Events
- 16 Feb 2015 Preclinical trials in Ocular hypertension in USA (Ophthalmic)
- 16 Feb 2015 Preclinical trials in Glaucoma in USA (Ophthalmic)